AKT Antagonist AZD5363 Influences Estrogen Receptor Function in Endocrine-Resistant Breast Cancer and Synergizes with Fulvestrant (ICI182780) In Vivo-Reference-Cited by-同舟云学术

AKT Antagonist AZD5363 Influences Estrogen Receptor Function in Endocrine-Resistant Breast Cancer and Synergizes with Fulvestrant (ICI182780) In Vivo

Published:2015-06-26 Issue:9 Volume:14 Page:2035-2048
ISSN:1535-7163
Container-title:Molecular Cancer Therapeutics
language:en
Short-container-title:Mol Cancer Ther

Author:

Ribas Ricardo,Pancholi Sunil,Guest Stephanie K.,Marangoni Elisabetta,Gao Qiong,Thuleau Aurélie,Simigdala Nikiana,Polanska Urszula M.,Campbell Hayley,Rani Aradhana,Liccardi Gianmaria,Johnston Stephen,Davies Barry R.,Dowsett Mitch,Martin Lesley-Ann

Publisher

American Association for Cancer Research (AACR)

Subject

Cancer Research,Oncology

Cited by 57 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. US Food and Drug Administration Approval Summary: Capivasertib With Fulvestrant for Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Locally Advanced or Metastatic Breast Cancer With PIK3CA/AKT1/PTEN Alterations;Journal of Clinical Oncology;2024-08-19

2. mTORC1-Driven Protein Translation Correlates with Clinical Benefit of Capivasertib within a Genetically Preselected Cohort of PIK3CA-Altered Tumors;Cancer Research Communications;2024-08-01

3. Efficacy and Safety of AKT Inhibitors in HR+/HER2- Breast Cancer or Metastatic TNBC: A Systematic Review and Meta-Analysis of Randomized Clinical Trials;2024-04-29

4. Capivasertib: A Novel AKT Inhibitor Approved for Hormone-Receptor-Positive, HER-2-Negative Metastatic Breast Cancer;Annals of Pharmacotherapy;2024-04-02

5. Boolean modeling of breast cancer signaling pathways uncovers mechanisms of drug synergy;PLOS ONE;2024-02-23